Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer

References

• Ferlay J SI , ErvikM, DikshitRet al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France (2013). http://globocan.iarc.fr
   Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics, 2018. CA Cancer J Clin.68(1), 7–30 (2018).
   PubMed Web of Science ®Google Scholar
• Pao W , ChmieleckiJ. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer10(11), 760–774 (2010).
   PubMed Web of Science ®Google Scholar
• Paez JG , JannePA, LeeJCet al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Shigematsu H , LinL, TakahashiTet al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst.97(5), 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Pao W , MillerV, ZakowskiMet al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101(36), 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA, KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362(25), 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Yu HA , RielyGJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J. Natl Compr. Canc. Netw.11(2), 161–169 (2013).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, HuCPet al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol.15(2), 213–222 (2014).
   PubMed Web of Science ®Google Scholar
• Shi YK , WangL, HanBHet al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a Phase 3, open-label, randomized study. Ann. Oncol.28(10), 2443–2450 (2017).
   PubMed Web of Science ®Google Scholar
• Lee CK , WuYL, DingPNet al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J. Clin. Oncol.33(17), 1958–1965 (2015).
   PubMed Web of Science ®Google Scholar
• Yu HA , ArcilaME, RekhtmanNet al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res.19(8), 2240–2247 (2013).
   PubMed Web of Science ®Google Scholar
• Wu SG , LiuYN, TsaiMFet al. The mechanism of acquired resistance to irreversible EGFR tyrosin kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget7(11), 12404–12413 (2016).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , ThressKS, AldenRSet al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol.34(28), 3375–3382 (2016).
   PubMed Web of Science ®Google Scholar
• Thress KS , BrantR, CarrTHet al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer90(3), 509–515 (2015).
   PubMed Web of Science ®Google Scholar
• Thompson JC , YeeSS, TroxelABet al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin. Cancer Res.22(23), 5772–5782 (2016).
   PubMed Web of Science ®Google Scholar
• Lanman RB , MortimerSA, ZillOAet al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE10(10), e0140712 (2015).
   PubMed Web of Science ®Google Scholar
• Yun CH , MengwasserKE, TomsAVet al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA105(6), 2070–2075 (2008).
   PubMed Web of Science ®Google Scholar
• Watanabe M , KawaguchiT, IsaSet al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin. Cancer Res.21(15), 3552–3560 (2015).
   PubMed Web of Science ®Google Scholar
• Liu Y , SunL, XiongZCet al. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco. Targets Ther.10, 2267–2279 (2017).
   PubMed Web of Science ®Google Scholar
• Yu HA , ArcilaME, HellmannMD, KrisMG, LadanyiM, RielyGJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann. Oncol.25(2), 423–428 (2014).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , MillerVA, RobsonMEet al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J. Thorac. Oncol.7(6), 1049–1052 (2012).
   PubMed Web of Science ®Google Scholar
• Tan CS , KumarakulasingheNB, HuangYQet al. Third generation EGFR TKIs: current data and future directions. Mol. Cancer17(1), 29 (2018).
   PubMed Web of Science ®Google Scholar
• Ward RA , AndertonMJ, AshtonSet al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem.56(17), 7025–7048 (2013).
   PubMed Web of Science ®Google Scholar
• Cross DA , AshtonSE, GhiorghiuSet al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov.4(9), 1046–1061 (2014).
   PubMed Web of Science ®Google Scholar
• Finlay MR , AndertonM, AshtonSet al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem.57(20), 8249–8267 (2014).
   PubMed Web of Science ®Google Scholar
• TAGRISSO® (osimertinib) [Package insert] AstraZeneca , Cambridge, UK (2018).
   Google Scholar
• Planchard D , BrownKH, KimDWet al. Osimertinib western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother. Pharmacol.77(4), 767–776 (2016).
   PubMed Web of Science ®Google Scholar
• Arcila ME , NafaK, ChaftJEet al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther.12(2), 220–229 (2013).
   PubMed Web of Science ®Google Scholar
• Yasuda H , KobayashiS, CostaDB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol.13(1), e23–e31 (2012).
   PubMed Web of Science ®Google Scholar
• Chen D , SongZ, ChengG. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther.9, 4181–4186 (2016).
   PubMed Web of Science ®Google Scholar
• Yang JC , SequistLV, GeaterSLet al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol.16(7), 830–838 (2015).
   PubMed Web of Science ®Google Scholar
• Floc’h N , MartinMJ, RiessJWet al. Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol. Cancer Ther.17(5), 885–896 (2018).
   PubMed Web of Science ®Google Scholar
• Janne PA , YangJC, KimDWet al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med.372(18), 1689–1699 (2015).
   PubMed Web of Science ®Google Scholar
• Yang JC , AhnMJ, KimDWet al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study Phase II extension component. J. Clin. Oncol.35(12), 1288–1296 (2017).
   PubMed Web of Science ®Google Scholar
• Goss G , TsaiCM, ShepherdFAet al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, Phase 2 study. Lancet Oncol.17(12), 1643–1652 (2016).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, AhnMJet al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , YangJC, LeeCKet al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol.36(9), 841–849 (2018).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Lee CK , NovelloS, RydenA, MannH, MokT. Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial. J. Clin. Oncol.36(18), 1853–1860 (2018).
   PubMed Web of Science ®Google Scholar
• Lee CK , ManJ, LordSet al. Checkpoint inhibitors in metastatic EGFR-Mutated non-small cell lung cancer-a meta-analysis. J. Thorac. Oncol.12(2), 403–407 (2017).
   PubMed Web of Science ®Google Scholar
• Lisberg A , CummingsA, GoldmanJWet al. A Phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J. Thorac. Oncol.13(8), 1138–1145 (2018).
   PubMed Web of Science ®Google Scholar
• Yu HA , TianSK, DrilonAEet al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol.1(7), 982–984 (2015).
   PubMed Web of Science ®Google Scholar
• Thress KS , PaweletzCP, FelipEet al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med.21(6), 560–562 (2015).
   PubMed Web of Science ®Google Scholar
• Ercan D , ChoiHG, YunCHet al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res.21(17), 3913–3923 (2015).
   PubMed Web of Science ®Google Scholar
• Niederst MJ , HuH, MulveyHEet al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res.21(17), 3924–3933 (2015).
   PubMed Web of Science ®Google Scholar
• Yang Z , YangN, OuQet al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin. Cancer Res.24(13), 3097–3107 (2018).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , HuY, MilehamKFet al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol.4(11), 1527–1534 (2018).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , ChengY, ZhouCet al. LBA50 – mechanisms of acquired resistance to first-line osimertinib: preliminary data from the Phase III FLAURA study. Presented at: ESMO. Munich, Germany19–23 October 2018.
   Google Scholar
• Minari R , BordiP, Del ReMet al. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer115, 21–27 (2018).
   PubMed Web of Science ®Google Scholar
• Ortiz-Cuaran S , SchefflerM, PlenkerDet al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin. Cancer Res.22(19), 4837–4847 (2016).
   PubMed Web of Science ®Google Scholar
• Naldini L , VignaE, NarsimhanRPet al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene6(4), 501–504 (1991).
   PubMed Web of Science ®Google Scholar
• Bottaro DP , RubinJS, FalettoDLet al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science251(4995), 802–804 (1991).
   PubMed Web of Science ®Google Scholar
• Lutterbach B , ZengQ, DavisLJet al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res.67(5), 2081–2088 (2007).
   PubMed Web of Science ®Google Scholar
• Benedettini E , ShollLM, PeytonMet al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol.177(1), 415–423 (2010).
   PubMed Web of Science ®Google Scholar
• Bean J , BrennanC, ShihJYet al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA104(52), 20932–20937 (2007).
   PubMed Web of Science ®Google Scholar
• Engelman JA , ZejnullahuK, MitsudomiTet al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science316(5827), 1039–1043 (2007).
   PubMed Web of Science ®Google Scholar
• Shi P , OhYT, ZhangGet al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett.380(2), 494–504 (2016).
   PubMed Web of Science ®Google Scholar
• Ou SI , AgarwalN, AliSM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer98, 59–61 (2016).
   PubMed Web of Science ®Google Scholar
• Piotrowska Z , ThressKS, MooradianMet al. Met amplification (amp) as a resistance mechanism to osimertinib. J. Clin. Oncol.35(15 Suppl.), 9020–9020 (2017).
   Google Scholar
• Ahn MEA . OA 09.03 TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI. J. Thorac. Oncol.12(11), S1768 (2017).
   Web of Science ®Google Scholar
• Eberlein CA , StetsonD, MarkovetsAAet al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res.75(12), 2489–2500 (2015).
   PubMed Web of Science ®Google Scholar
• Shi P , OhYT, DengLet al. Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation. Clin. Cancer Res.23(21), 6567–6579 (2017).
   PubMed Web of Science ®Google Scholar
• Ley R , EwingsKE, HadfieldK, CookSJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ.12(8), 1008–1014 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas LW , LamC, EdwardsSW. Mcl-1; the molecular regulation of protein function. FEBS Lett.584(14), 2981–2989 (2010).
   PubMed Web of Science ®Google Scholar
• Domina AM , VranaJA, GregoryMA, HannSR, CraigRW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene23(31), 5301–5315 (2004).
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov: NCT02803203. https://clinicaltrials.gov/ct2/show/NCT02803203
   Google Scholar
• Clinicaltrials.gov: NCT02803203. https://clinicaltrials.gov/ct2/show/NCT03392246
   Google Scholar
• Clinicaltrials.gov: NCT02503722. https://clinicaltrials.gov/ct2/show/NCT02503722
   Google Scholar
• Clinicaltrials.gov: NCT02496663. https://clinicaltrials.gov/ct2/show/NCT02496663
   Google Scholar
• Clinicaltrials.gov: NCT03433469. https://clinicaltrials.gov/ct2/show/NCT03433469
   Google Scholar
• Wu YL , HerbstRS, MannH, RukazenkovY, MarottiM, TsuboiM. ADAURA: Phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin. Lung Cancer19(4), e533–e536 (2018).
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov: NCT03521154. https://clinicaltrials.gov/ct2/show/NCT03521154?id=NCT03072043+OR+NCT02935361+OR+NCT03521154&rank=1&load=cart
   Google Scholar